Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Other Non-Current Liabilities (2016 - 2025)

Altimmune (ALT) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $5.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 22188.46% to $5.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.8 million, a 22188.46% increase, with the full-year FY2024 number at $5.3 million, up 13225.0% from a year prior.
  • Other Non-Current Liabilities was $5.8 million for Q3 2025 at Altimmune, up from $5.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $7.0 million in Q3 2021 to a low of $16000.0 in Q1 2025.
  • A 5-year average of $3.3 million and a median of $4.8 million in 2021 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 99.01% in 2022, then soared 22188.46% in 2025.
  • Altimmune's Other Non-Current Liabilities stood at $6.1 million in 2021, then tumbled by 99.01% to $60000.0 in 2022, then crashed by 33.33% to $40000.0 in 2023, then skyrocketed by 13225.0% to $5.3 million in 2024, then grew by 8.72% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Other Non-Current Liabilities are $5.8 million (Q3 2025), $5.4 million (Q2 2025), and $16000.0 (Q1 2025).